top of page
Xcelom Limited (Global)
Knowledge Hub
Meet the Xcelom Team at PacBio Prism 2026 — Fukuoka, Japan | May 11–13
We are excited to announce that the Xcelom team, together with our parent company Berry Genomics and our partner Haorui Genomics, will be at PacBio Prism 2026 — PacBio's annual conference for researchers and genomics experts exploring the future of long-read sequencing. It is one of the best opportunities to learn about LRS breakthroughs and meet the people shaping the field. Last year, our Head of R&D, Dr. Aiping Mao, gave an exciting talk on Berry Genomics' experience in ap
Building a Targeted LRS Panel for Newborn CAH Screening
How Long-Read Sequencing resolves the CYP21A2-TNXB highly homologous pseudogene challenge and enhances first-tier screening. Introduction: The Evolution of Newborn Screening Compared to traditional biochemical assays, Genetic Newborn Screening (NBS) offers a distinct advantage: clearer results, reduced unnecessary follow-up, and the ability to detect conditions that lack early-stage biochemical markers. Thanks to advancements in sequencing technology, laboratories can now sc
bottom of page